$50.45
+5.18
(+11.44%)▲
Bristol-Myers Squibb Co is a biopharmaceutical company that is involved in the development and commercialization of drugs for various diseases.
5.05%
Downside
Day's Volatility :5.34%
Upside
0.3%
22.62%
Downside
52 Weeks Volatility :35.39%
Upside
16.5%
Period | Bristol-myers Squibb Co. | Sector (Health Care) | S&P500 |
---|---|---|---|
3 Months | 0.94% | 6.5% | 5.9% |
6 Months | -8.91% | 7.1% | 10.4% |
1 Year | -28.61% | 9.8% | 18.2% |
3 Years | -33.12% | 14.2% | 22.1% |
Market Capitalization | 91.8B |
Book Value | $8.14 |
Dividend Share | 2.34 |
Dividend Yield | 5.37% |
Earnings Per Share (EPS) | -3.14 |
PEG Ratio | 31.35 |
Wall Street Target Price | 45.47 |
Profit Margin | -13.5% |
Operating Margin TTM | 19.25% |
Return On Assets TTM | 5.39% |
Return On Equity TTM | -25.33% |
Revenue TTM | 45.5B |
Revenue Per Share TTM | 22.21 |
Quarterly Revenue Growth YOY | 4.7% |
Gross Profit TTM | 36.4B |
EBITDA | 18.2B |
Diluted Eps TTM | -3.14 |
Quarterly Earnings Growth YOY | -0.09 |
EPS Estimate Current Year | 0.47 |
EPS Estimate Next Year | 6.31 |
EPS Estimate Current Quarter | -4.44 |
EPS Estimate Next Quarter | 1.75 |
What analysts predicted
Downside of 9.87%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 22.6B | ↑ 8.59% |
Net Income | 5.0B | ↑ 391.76% |
Net Profit Margin | 21.95% | ↑ 17.1% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 26.1B | ↑ 15.89% |
Net Income | 3.4B | ↓ 30.55% |
Net Profit Margin | 13.15% | ↓ 8.8% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 42.5B | ↑ 62.62% |
Net Income | -9.0B | ↓ 361.56% |
Net Profit Margin | -21.16% | ↓ 34.31% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 46.4B | ↑ 9.09% |
Net Income | 7.0B | ↓ 177.75% |
Net Profit Margin | 15.08% | ↑ 36.24% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 46.2B | ↓ 0.49% |
Net Income | 6.3B | ↓ 9.54% |
Net Profit Margin | 13.71% | ↓ 1.37% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 45.0B | ↓ 2.5% |
Net Income | 8.0B | ↑ 26.84% |
Net Profit Margin | 17.83% | ↑ 4.12% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 11.4B | ↑ 1.68% |
Net Income | 2.0B | ↑ 25.9% |
Net Profit Margin | 17.73% | ↑ 3.41% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 11.3B | ↓ 0.6% |
Net Income | 2.3B | ↑ 11.87% |
Net Profit Margin | 19.95% | ↑ 2.22% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 11.2B | ↓ 0.98% |
Net Income | 2.1B | ↓ 8.36% |
Net Profit Margin | 18.47% | ↓ 1.48% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 11.0B | ↓ 2.32% |
Net Income | 1.9B | ↓ 6.99% |
Net Profit Margin | 17.58% | ↓ 0.89% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 11.5B | ↑ 4.66% |
Net Income | 1.8B | ↓ 8.61% |
Net Profit Margin | 15.35% | ↓ 2.23% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 11.9B | ↑ 3.38% |
Net Income | -11.9B | ↓ 775.99% |
Net Profit Margin | -100.39% | ↓ 115.74% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 10.7B | ↓ 68.23% |
Total Liabilities | 7.3B | ↓ 66.14% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 129.9B | ↑ 1119.1% |
Total Liabilities | 78.2B | ↑ 964.72% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 118.5B | ↓ 8.82% |
Total Liabilities | 80.6B | ↑ 3.01% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 109.3B | ↓ 7.74% |
Total Liabilities | 73.3B | ↓ 9.05% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 96.8B | ↓ 11.43% |
Total Liabilities | 65.7B | ↓ 10.38% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 95.2B | ↓ 1.72% |
Total Liabilities | 65.7B | ↓ 0.04% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 96.8B | ↓ 1.4% |
Total Liabilities | 65.7B | ↑ 0.37% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 94.3B | ↓ 2.62% |
Total Liabilities | 62.4B | ↓ 5.03% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 93.5B | ↓ 0.84% |
Total Liabilities | 61.5B | ↓ 1.5% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 91.3B | ↓ 2.38% |
Total Liabilities | 62.2B | ↑ 1.21% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 95.2B | ↑ 4.27% |
Total Liabilities | 65.7B | ↑ 5.58% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 99.0B | ↑ 4.07% |
Total Liabilities | 82.5B | ↑ 25.59% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 5.9B | ↑ 12.61% |
Investing Cash Flow | -874.0M | ↑ 1224.24% |
Financing Cash Flow | -3.5B | ↓ 13.29% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 8.1B | ↑ 35.81% |
Investing Cash Flow | -9.8B | ↑ 1017.85% |
Financing Cash Flow | 7.6B | ↓ 315.59% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 14.1B | ↑ 74.19% |
Investing Cash Flow | -10.9B | ↑ 11.15% |
Financing Cash Flow | -1.2B | ↓ 115.1% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 16.2B | ↑ 15.34% |
Investing Cash Flow | -538.0M | ↓ 95.05% |
Financing Cash Flow | -16.2B | ↑ 1309.56% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 13.1B | ↓ 19.38% |
Investing Cash Flow | -1.1B | ↑ 97.4% |
Financing Cash Flow | -17.0B | ↑ 4.55% |
FY23 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 13.9B | ↑ 6.08% |
Investing Cash Flow | -2.3B | ↑ 116.1% |
Financing Cash Flow | -9.4B | ↓ 44.49% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 3.3B | ↓ 10.33% |
Investing Cash Flow | 1.2B | ↓ 158.29% |
Financing Cash Flow | -3.2B | ↓ 28.55% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 3.0B | ↓ 10.16% |
Investing Cash Flow | -210.0M | ↓ 117.31% |
Financing Cash Flow | -3.1B | ↓ 6.04% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 1.9B | ↓ 36.46% |
Investing Cash Flow | -329.0M | ↑ 56.67% |
Financing Cash Flow | -2.2B | ↓ 28.75% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 4.8B | ↑ 151.78% |
Investing Cash Flow | -410.0M | ↑ 24.62% |
Financing Cash Flow | -5.2B | ↑ 137.46% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 4.3B | ↓ 10.5% |
Investing Cash Flow | -1.3B | ↑ 228.29% |
Financing Cash Flow | 967.0M | ↓ 118.74% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 2.8B | ↓ 33.35% |
Investing Cash Flow | -19.6B | ↑ 1357.5% |
Financing Cash Flow | 14.6B | ↑ 1414.37% |
Sell
Neutral
Buy
Bristol-myers Squibb Co. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Bristol-myers Squibb Co. | 6.52% | -8.91% | -28.61% | -33.12% | -0.22% |
Eli Lilly And Company | -8.88% | 28.46% | 81.04% | 237.65% | 658.46% |
Johnson & Johnson | 8.73% | 0.09% | -7.57% | -7.12% | 22.11% |
Merck & Co. Inc. | -4.3% | 4.16% | 17.46% | 62.93% | 54.55% |
Abbvie Inc | 6.44% | 10.81% | 28.38% | 54.66% | 168.85% |
Amgen Inc. | 6.87% | 7.23% | 42.13% | 36.4% | 90.66% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Bristol-myers Squibb Co. | 12.66 | NA | 31.35 | 0.47 | -0.25 | 0.05 | 0.05 | 8.14 |
Eli Lilly And Company | 129.92 | 129.92 | 1.43 | 13.75 | 0.51 | 0.13 | 0.01 | 14.23 |
Johnson & Johnson | 23.93 | 23.93 | 0.89 | 10.01 | 0.24 | 0.08 | 0.03 | 29.09 |
Merck & Co. Inc. | 141.48 | 141.48 | 0.1 | 8.16 | 0.05 | 0.1 | 0.02 | 15.94 |
Abbvie Inc | 52.29 | 52.29 | 0.45 | 9.93 | 0.56 | 0.08 | 0.04 | 4.54 |
Amgen Inc. | 47.88 | 47.88 | 2.39 | 17.96 | 0.73 | 0.05 | 0.03 | 9.36 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Bristol-myers Squibb Co. | Hold | $91.8B | -0.22% | 12.66 | -13.5% |
Eli Lilly And Company | Buy | $790.8B | 658.46% | 129.92 | 17.08% |
Johnson & Johnson | Buy | $376.1B | 22.11% | 23.93 | 43.91% |
Merck & Co. Inc. | Buy | $318.9B | 54.55% | 141.48 | 3.76% |
Abbvie Inc | Buy | $311.2B | 168.85% | 52.29 | 11.02% |
Amgen Inc. | Buy | $180.0B | 90.66% | 47.88 | 12.74% |
Insights on Bristol-myers Squibb Co.
Revenue is up for the last 3 quarters, 10.96B → 11.86B (in $), with an average increase of 3.9% per quarter
Netprofit is down for the last 5 quarters, 2.26B → -11.91B (in $), with an average decrease of 200.0% per quarter
In the last 1 year, Eli Lilly And Company has given 81.0% return, outperforming this stock by 109.6%
In the last 3 years, Eli Lilly And Company has given 237.6% return, outperforming this stock by 270.7%
Vanguard Group Inc
BlackRock Inc
State Street Corporation
JPMorgan Chase & Co
Capital Research & Mgmt Co - Division 3
Charles Schwab Investment Management Inc
In the quarter ending March,2024. Bristol-myers Squibb Co. has declared dividend of $0.6
Read MoreThe Bristol-Myers Squibb Company is an American multinational pharmaceutical company. Headquartered in New York City, BMS is one of the worlds largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest U.S. corporations. For fiscal 2022, it had a total revenue of $46.2 billion.
Organization | Bristol-myers Squibb Co. |
Employees | 34100 |
CEO | Dr. Christopher S. Boerner Ph.D. |
Industry | Health Technology |
Cubesmart
$50.45
+11.44%
Iqvia Holdings Inc.
$50.45
+11.44%
Microsectors Travel 3x Inlev
$50.45
+11.44%
Jack Henry & Associates Inc.
$50.45
+11.44%
Packaging Corporation Of America
$50.45
+11.44%
Cognizant Technology Solutions Corp.
$50.45
+11.44%
Synopsys Inc.
$50.45
+11.44%
Targa Resources Corp.
$50.45
+11.44%
Parker-hannifin Corporation
$50.45
+11.44%